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Background and Objectives. Culture expanded multipotential stromal cells (MSCs) have considerable potential for bone
regeneration therapy but their wider use is constrained by the lack of simple and predictive assays of functional potency. Extended
passaging leads to loss of multipotency but speed of decline depends on MSC donor age. The aim of this study was to develop
an assay predictive of MSC culture longevity applicable to a broad donor age range. Materials and Methods. Bone marrow (BM,
𝑛 = 7) was obtained from a diverse range (2–72 years) of healthy donors. MSCs were culture expanded to senescence and their
osteoprogenitor content, gene expression profiles, epigenetic signature, and telomere behaviour weremeasured throughout. Output
data was combined for modelling purposes. Results. Regardless of donor age, cultures’ osteoprogenitor content correlated better
with remaining lifespan (population doublings before senescence, PD-BS) than proliferative history (accrued PDs). Individual
gene’s expression or telomere length did not predict PD-BS but methylation of individual CpG islands did, PRAMEF2 in particular
(𝑟 = 0.775). Coupling the steep relationship of relative SPARC expression with PD-BS (𝑟 = −0.753) the formula SPARC ×
1/PREMEF2 gave an improved correlation (𝑟 = −0.893).Conclusion. A formula based on SPARCmRNAandPRAMEF2methylation
may be used to predict remaining BM-MSC longevity and related loss of multipotentiality independent of donor age.
1. Introduction
Bonemarrow (BM)multipotential stromal cells (MSCs), also
termed skeletal stem cells [1, 2] or mesenchymal stromal cells
[3], have considerable potential for bone regeneration. To
date, preclinical and clinical studies have been conducted
using both culture expanded and noncultured BMMSCs and
showed promising, but often variable, clinical results [4].This
could be due to the current lack of robust quality control
assays to determine cultures’ functional potencies prior to
implantation.
Batch testing of MSCs for their purity control is estab-
lished based on cell surface markers [5]. Screening of an indi-
vidual batch’s longevity and differentiation capacity is gener-
ally not performed by MSC manufacturers but is important
to consider in order to ensure consistent clinical results.
The number of cells needed for transplantation is the key
issue in the field, particularly for very large bone defects, and
is the reason why significant culture expansion is in many
cases unavoidable; however it is known to lead to a gradual
loss of multipotentiality and an increase in the proportion of
senescent cells [6] (a phenomenon termed “MSC replicative
ageing”) [7]. It is common for MSCs to be introduced to
a patient following approximately 3 passages in culture but
this in itself is not a precise measure of replicative ageing
as cumulative population doublings (PDs) are dependent
upon the initial numbers of seeded MSCs. Furthermore,
cumulative PDs at passage 3 (p3) are unlikely to be indicative
of the culture’s remaining lifespan, which is related to both
cumulative PDs and donor age [8–10].
The aim of this study was to develop a predictive test
for the remaining lifespan and functionality of cultured BM
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MSCs based on the dynamics of gene expression alone or
in combination with other parameters [11], which would be
applicable throughout culture expansion stages and valid
regardless of donor age. The DNA-methylation status of
six CpG sites was investigated as a representation of the
proximity of cellular senescence in relation to the stage of in
vitro culture [12]. Gene expression and CpG methylation
levels were combined in order to propose the most predictive
model.
2. Materials and Methods
2.1. Generation ofMSCCultures. Iliac crest BMaspirates were
obtained from 7 healthy donors following informed written
consent (mean donor age 28.4 years; male 2, 20, 22, 22, and
72 years, female 19, 35 years). Ethical approval (06/Q1206/127
and 07/Q1205/27) was obtained from the National Research
Ethics Committee (Yorkshire and Humberside).
MSC cultures were established from 100 𝜇L of BM aspi-
rate seeded into 10 cm dishes and expanded in Alpha-MEM
(Life Technologies, Paisley, UK) containing 10% FBS (PAA,
Little Chalfont, UK) and 1 ng/mL FGF2 (PeproTech, Lon-
don, UK) [13]. Three donor marrows (22, 35, and 72
years) were also expanded in StemMACS medium (Miltenyi
Biotec, Bisley, UK). Cultures were maintained with twice
weekly half media changes. At day 21, population doublings
(PDs) were calculated using following equation: PD =
log 2(cell count on day 21/CFU-F on day 0); this culture was defined as
p0. CFU-Fs (colony-forming units-fibroblast) on day 0 were
determined from two further replicate dishes that were
enumerated on day 14 following Crystal Violet staining; one
colony was defined as >50 cells [14]. The remainder of the
samples were passaged at the cell seeding density of 4500/cm2
and expanded to senescence, defined as less than 1 PD
achieved in 7 days (presenescent being the previous passage)
[15]. BM-MSC cultures were established and maintained by
two individuals (SC and SB) who worked exclusively with
each culture.
2.2. Flow Cytometry. To prove cultures’ MSC identity p1 and
p3 cultures were trypsinised and stained with the follow-
ing antibodies: CD90-PE, CD105-PE, CD31-FITC (all from
Serotec, Kidlington, UK), CD73-PE, CD34-PerCp, CD45-
PE-Cy7, CD19-FITC, CD14-PE, CD146-PE, and HLA-DR-
FITC (all from BD Biosciences, Oxford, UK). All antibodies
were used at manufacturers’ recommended concentrations
and the data were collected and analysed using a LSRII flow
cytometer equipped with FACSDiva Software (both from BD
Biosciences).
2.3. The Assessment of MSC Osteogenic Capacity at the Clonal
Level. Colony-forming unit-osteoblast (CFU-O) assays were
performed with culture expanded cells at regular intervals
throughout their culture period. For each assay, 500 MSCs
were seeded into 6 replicate 3 cmdishes inmedia as described
above; on day 8 colonies were washed in PBS and the
medium changed to standard osteogenic medium [16]. Half
media changes were carried out twice weekly. After 14 days,
alkaline phosphatase activity assays were performed (𝑛 = 2
dishes), and after 21 days calcium production assays (𝑛 = 3
dishes) were carried out and calcium levels were determined
following HCL extraction using calcium liquid (Sentinel
Diagnostics, Milan, Italy) [16]. Osteogenically differentiated
MSCs from the 6th dish were used for qPCR at day 21.
2.4.Quantitative Real-TimePCR. Aliquots of culture expand-
ed MSCs were lysed during passage and oMSCs directly in
the dish using lysis buffer from an RNA/DNA/protein kit
(Norgen Biotek, Thorold, Canada). RNA and genomic (g)
DNA were used in this study. RNA from senescent cells was
not used due to degradation. RNA was reverse transcribed
to cDNA using High Capacity reverse transcription kit and
gene expression was measured by quantitative real-time PCR
(qPCR) using a 96-gene Custom Taqman Array (both from
Life Technologies) [17]. Genes were selected to encompass
the multipotential nature of MSCs with particular emphasis
on the bone lineage since the focus of this study was
their osteogenic capacity. Seventy-nine experimental genes
were studied on all samples (assay identification in [17]).
Relative expression was calculated using the 2(−ΔCt) method
normalising to the reference gene HPRT. Level of induction
was established using 2(−ΔΔCt).
2.5. Telomere Length Measurements. Relative telomere
lengthsweremeasured in 20 ng gDNAby qPCR amplification
of telomere repeats (T) in relation to a single copy gene, 36B4
(S); the subsequent T : S ratio enabled calculation of telomere
length in base pairs (bp) [18]. Reaction components were 2x
SYBR Green PCR Master Mix (ThermoFisher) and primers
Tel1 (270 nM), Tel2 (900 nM), 36B4u (300 nM), and 36B4d
(500 nM) [18] (Eurofins Genomics, Ebersberg, Germany).
2.6. Methylation Signature. To track the state of cellular
senescence with regard to accrued PD, the level of methyla-
tion of six CpG islands was measured in twenty-four gDNA
samples (from 7 donors) from across the expansion period
according the method of Koch [12] by Cygenia GmbH
(Aachen, Germany).
2.7. Statistical Analysis. Statistical analysis was performed
using IBM SPSS Statistics 21. Normality of age and p0 PD
distributions were determined using the Shapiro-Wilk test
(𝑝 = 0.118 and 0.073, resp.). Correlations were defined using
Spearman’s rho correlations. Paired analysis of gene expres-
sion data was carried out with Wilcoxon Signed Rank test as
the datawas nonparametric andMann–Whitneywas used for
comparison of calculated groups. Gradients were determined
from Microsoft Excel equation of the line function. Confi-
dence interval figures were prepared using GraphPad Prism
7.02.
3. Results
3.1. Basic Characterisation of Culture Expanded MSCs. Cul-
tivation of MSCs from a widely distributed age range (2–
72 years) demonstrated that the longevity of cultures was
vastly different and that senescence occurred after a variable
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Figure 1: Basic characterisation of culture expanded MSCs. (a) Four donors representing the variable longevity of MSC cultures which is (b)
dependent upon donor age (𝑛 = 7). (c) Confirmation of the ISCT phenotype for MSCs at passage 1 (15.24 PD ± 0.35) and (d) passage 3 (20.23
PD ± 1.4), 𝑛 = 3. Error bars are standard deviation.
number of PDs (Figure 1(a) illustrates 4 of the 7 cultures).
The number of PDs that occurred prior to senescence
correlated negatively with donor age (Figure 1(b)) [9, 10, 16].
Throughout culture expansion, the cells maintained their
MSC phenotype; phenotypic data for p1 and p3 cultures (𝑛 =
3, corresponding to mean 15.2 and 20.2 PDs, resp.) are shown
in Figure 1(c).
Subsequently, and in order to identify markers represen-
tative of function and utility rather than individual donor
specific trends, data from all donors were pooled and studied
collectively.
3.2. Osteoprogenitor Capacity of MSCs at Different Stages of
Cultivation. Consistent with previous studies [16, 19], grad-
ual loss of osteogenic colonies (CFU-O) was observed in all
donor cultures (series from one donor shown in Figure 2(a)).
However, using pooled data (representing donor diversity),
although CFU-O decline was still observed, it was evident
that neither CFU-O nor calcium production had strong
relationships with accrued PDs (Figure 2(b) top), that is, with
cultures’ in vitro age. Much stronger, statistically significant,
correlations were found for both CFU-O and Ca++ depo-
sition against PD-BS (Figure 2(b) bottom) indicating their
dependence on both accrued PDs and donor age (a factor
determining cultures’ longevity) [9, 10].
Additionally, the upregulation (2−ΔΔCt) of theALPL (alka-
line phosphatase) gene in response to osteogenic stimulation
was also significant in relation to PD-BS (𝑟 = 0.470, 𝑝 =
0.020), but not PD (𝑟 = 0.026).
3.3. Gene Expression ofMSCs at Different Stages of Cultivation.
Initially, gross gene expression changes were measured at
passage 0 (mean 14.8 PD) and compared to their presenescent
state (passage immediately prior to <1 PD in 1 week; mean
29.9 PD). As might be expected from age-diverse samples
the spread of gene expression was often broad and therefore
statistical analysis suggested that the RNA message of the
majority of themolecules tested (60/79 genes) did not change
between these two stages (𝑝 > 0.05; no change also stated
if less than 2-fold change). The genes showing the greatest
mean fold increase at presenescence were TNFRSF11B (13-
fold) and FZD4 (5-fold) with 13 others exhibiting 2–4-fold
increases (Supplementary Figure 1 in Supplementary Mate-
rial available online at https://doi.org/10.1155/2017/6129596).
Twomolecules,NANOG (84-fold) andTWIST1 (5-fold), were
significantly lower at presenescence andWIF1 became unde-
tectable in 6/7 samples. As well as being themost upregulated
molecule at presenescence, TNFRSF11B/osteoprotegerin also
had the strongest relationship with accrued PD (followed
by SPARC/osteonectin (Figure 3(a)). Negative relationships
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Figure 2: MSC osteogenic capacity in relation to PD and remaining PD, before senescence. (a) Decline in osteogenic differentiation capacity
of MSCs from a representative donor (alkaline phosphatase). (b) Functional measures of osteogenesis. PD: population doubling; PD-BS:
population doubling before senescence.
were observed for a markers of stem cell pluripotency [20]:
NANOG and SOX2, MSC marker NGFR [21], and Wnt
regulators; SFRP1 andWIF1, as well as TWIST1 and TWIST2
(not shown) and adipogenesis markers, namely, CEBPA and
FABP4 (Figure 3(a)). Chondrogenesis-associated molecules
showed no obvious relationship with PD (Supplementary
Figure 2). Overall, and regardless of donor age, culture
expansion appeared to cause the loss of pluripotency and
adipogenic markers whilst cultures’ osteogenic commitment
increased (evident by increases in mature osteoblast markers
such as SPARC and TNFRSF11B/osteoprotegerin). Combined
with functional data on the loss of CFU-O with accrued
PDs (Figure 2), these data indicated that late passage cultures
comprised poorly proliferative, osteogenically committed
cells on their way to senescence.
When considered at all time points, osteogenic stimula-
tion caused the upregulation of several (24) genes, but only
four were reduced (Table 1). However, when gene expression
was compared before and after osteogenic induction longitu-
dinally in relation to PD-BS, responses fell into 4 categories:
(1) upregulated, (2) downregulated, (3) noninducible, and (4)
passage/time variable (Figure 3(b) and Supplementary Figure
3). Some molecules were always upregulated, such as FRZB
and OMD, whereas TNFRSF11B and ALPL became less in-
duced closer to senescence as the basal level itself is increased.
Whilst these data showed that inability to further upregu-
late TNFRSF11B and ALPL could be a feature of presenescent
MSCs and hence be indicative of culture’s remaining lifespan,
its value as a predictive test is low, since osteogenic differen-
tiation assays are notably very time consuming. With this in
mind, postinduction marker expression was not considered
for prediction purposes.
3.4. Identification of Gene Transcripts and Other Parame-
ters with Predictive Potential for MSC Culture Longevity.
The search for predictive markers was next narrowed to
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Figure 3: Gene expression changes with time in vitro and effect of osteoinduction. (a) Transcripts with the strongest relationship
with PD (36 points from 7 donors). (b) Induced gene expression patterns compared to undifferentiated MSCs throughout culture
expansion. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01. (b) Upregulated genes; (c) time/passage variable genes; solid diamond/line undifferentiated MSCs; hollow
diamond/dotted line osteodifferentiated MSCs.
those gene transcripts showing strong correlations with both
PDs and PD-BS (Table 2), although association with all
four measures (PD, PD-BS, CFU-O, and Ca++ deposition)
was required for candidature and those with the strongest
potential (relationship with PD-BS rho > 0.6) were BMPER,
SPARC, and TNFRSF11B (Table 2). None of these were strong
enough in isolation to be predictive at 95% confidence
(Supplementary Figure 4). In having the steepest gradient
in addition to its functional correlations (Table 2) SPARC
was the leading candidate for use in conjunction with other
known MSC replicative ageing-associated factors: telomere
measurement [9] and gene methylation markers [12], both
of which were investigated independently and for possible
inclusion with SPARC. Importantly, when tested in a second
medium, StemMACS, SPARC retained its relationships with
PD-BS and PD, whereas BMPER and TNFRSF11B did not
(Supplementary Figure 5). Standard MSC surface markers
were not considered for this analysis as they showed no
changes with accrued PDs (Figure 1(c)). However, CD mark-
ers were comprehensively tested in Siegel et al. [22], where
several candidate molecules were identified for consideration
in predictive testing.
As expected for this age-diverse cohort, no significant
relationship was found between the telomere lengths and
PD or PD-BS (latter shown in Figure 4(a) left). However,
the process of clonal differentiation itself lowered the T/S
ratio (the relative measure of telomere to single copy gene)
[23] which equated to a reduction in telomere length by
a median value of 94 bp (23 points from 4 donors, 𝑝 =
0.038) which may be representative of the fact that colony-
forming cells were plated at a low density and were allowed
to proliferate before being placed in osteogenic conditions.
When combined with SPARC (SPARC × [undifferentiated
T/S ratio]), a correlation was observed in relation to PD-
BS; however the majority of the points (63%) fell outside
of the 95% confidence limits (Figure 4(a) right); therefore
application of T/S ratios was not pursued further.
Another potential marker of MSC replicative ageing,
DNA methylation, was independently investigated (blind)
with regard to MSCs’ predicted passage number (PPN).
The PPN was deduced by testing six CpG islands [12] and
correlated strongly with actual cumulative/accrued PD and
PD-BS (𝑟 = 0.949, 𝑝 = 1×10−14 and 𝑟 = −0.788, 𝑝 = 2×10−6,
resp., data not shown). When the individual CpG islands
were studied, their methylation levels remained more closely
correlated with PD (Table 3); however positive associations
with PD-BS for PRAMEF2, SELP, KRTAP13-3, and CASP14
were observed. None of the CpG islands showed any signif-
icant relationship with osteogenic capacity (CFU-O or Ca++
deposition).
Utilizing the strength of the CpG island correlations
with PD and PD-BS (Table 3) and relative levels of SPARC
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Table 1: Genes upregulated following osteogenic induction.
Gene Fold upregulation Significance
(all time points)
FRZB 256.9 ∗∗∗∗
OMD 72.4 ∗∗∗∗
PDGFRL 55.7 ∗∗∗∗
LEPR 29.2 ∗∗∗∗
IGF2 22.6 ∗∗∗∗
NGFR 19.6 ∗
MSX1 10.4 ∗∗
ANGPTL4 8.2 ∗∗∗∗
MT2A 7.7 ∗∗∗∗
SFRP1 7.3 ∗∗∗∗
TGFBR2 5.7 ∗∗∗∗
TGFBR3 5.7 ∗∗∗∗
SPP1 5.5 ∗∗∗∗
ALPL 4.9 ∗∗∗∗
SORT1 4.4 ∗∗∗∗
DVL2 3.2 ∗∗∗∗
PDGFRA 3.2 ∗∗∗∗
BMPER 2.8 ∗∗
S1PR1 2.8 ∗∗∗∗
FZD1 2.7 ∗∗∗∗
CSPG4 2.6 ∗∗∗∗
FZD4 2.5 ∗∗∗∗
NGFRAP1 2.4 ∗∗∗
FGFR1 2.1 ∗∗∗∗
SOX9 0.5 ∗∗
NES 0.4 ∗∗
VEGFA 0.3 ∗∗∗∗
SFRP4 0.2 ∗∗
Only genes with significant >2-fold induction: ∗𝑝 < 0.05, ∗∗𝑝 < 0.01,
∗∗∗𝑝 < 0.001, and ∗∗∗∗𝑝 < 0.0001.
mRNA with osteogenic capacity, PD, and PD-BS (Table 2),
calculations incorporating these values were also tested for
more robust predictability. The relative level of SPARC was
multiplied by methylation value for islands with positive
associations with PD (CASR and GRM7) or reciprocal value
for negative associations (PRAMEF2, SELP, CASP14, and
KRTAP13-3). Correlations were observed for all tests for both
PD (𝑟 ≥ 0.589, 𝑝 ≤ 0.003) and PD-BS (𝑟 ≥ 0.794,
𝑝 ≤ 6 × 10−6); however only PD-BS was considered further
for predictive capability. With more than 5 remaining PD-
BS, all points (except one) fell within the 95% confidence
limits for SPARC × [1/PRAMEF2] (Figure 4(b)). This calcu-
lation additionally had the strongest correlation with CFU-
O (Figure 4(b)) although it is notable that all SPARC/CpG
relationships correlated with CFU-O (𝑟 > −0.532, 𝑝 <
0.05). Using an arbitrary calculation value for SPARC ×
[1/PRAMEF2] of ≤5 against calculated trend lines (𝑦 =
0.0778𝑥+11.683), SPARC × [1/PRAMEF2] yielded remaining
≥15 PD-BS, and ≥86 CFU-O/500 MSCs. Even when reduced
to 95% confidence this value (SPARC × [1/PRAMEF2] ≥ 5)
could predict ≥10 PD-BS (Figure 4(c) left) and ≥62 CFU-
O/500 MSCs (Figure 4(c) right). If the calculated value was
greater than five then there would be no guarantee (95%
confidence limit) ofmore than 5 PDs remaining before senes-
cence. The differences in the above or below five categories
were highly significant (Figure 4(c)); therefore the calculation
could be considered reliable and could be applied early in
MSC culture expansion.
4. Discussion
Since MSCs have great therapeutic potential for tissue rescue
and repair [24], the ability to predict the utility and potency
of a BM-MSC sample prior to or at an early stage of culture
expansion would be invaluable. For bone repair applications,
and particularly for large bone defect reconstruction, the
cells’ ability to proliferate and populate the void prior to
differentiation is paramount; indeed >1500 cells per cm3 are
required for bone union according to Hernigou et al. [25].
Some predictions about MSC proliferation lifespan can be
made with regard to MSC donor age [9, 10] but donor age
alone is likely to be a very poor predictor as some studies
reported no clear association [26] and it does not take into
account a culture’s in vitro proliferative history. Molecular
markers indicative of MSC replicative ageing have been
investigated previously [6, 22, 27, 28]; however in this study
efforts were made to combine these two essential factors
and to develop a predictive test of the culture’s remaining
proliferative capacity applicable to a broad donor age range
and independent of its previous replicative history.
The MSCs used in this study represented a broad biolog-
ical donor age range (70 years) testing both young and old
extremes in an exaggerated model investigating molecular
markers throughout culture expansion up to senescence thus
allowing putative markers to be thoroughly scrutinized. All
cultures had a typical MSC phenotype and their lifespans
to senescence correlated with donor age, as expected [8–
10]. Many MSC-related gene transcripts [17, 29, 30] showed
no significant changes from p0 to senescence; this was not
unexpected given the magnitude of change that has already
occurred from the native (uncultured) state to early passage
MSCs [17, 31]. Though the cohort size was small, the range
of proliferation, time (days) and PD, observed with respect
to donor age agreed with previous studies relating to human
MSCs [8–10]. That NANOG, TWIST1, and WIF1 declined
during expansion was not unexpected since all have been
subjects of increased proliferation studies [32–34] which is
indicative of the known loss of MSC multipotency during
extended cultivation [35, 36].
When the behaviour osteogenesis-related and other genes
were investigated in relation to MSC replicative ageing status
(measured by PDs), an increased expression of many genes
was found. This strongly supported the notion that MSCs
progressively commit to osteogenic lineage during prolonged
cultivation [7, 37] parallel with the loss of multipotentiality.
Interestingly, this was further supported by genes such as
TNFRSF11B and ALPL no longer needing to be upregulated
closer to senescence as the uninduced levels matched the
osteoinduced levels of the younger cultures/earlier passages.
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Table 2: Transcript relationships with PD-BS and osteoprogenitor indicators.
Gene Correlation with PD-BS(rho = (𝑝)) Gradient
Range
(min–max)
Also related
to PD?
Relationship
with CFU-O?
Relationship
with Ca++?
Higher expression
closer to senescence
ACVR2A −0.454∗∗ −0.0727 0.07–3.41 Y Y Y
ALPL −0.348∗ −0.1095 0.03–5.26 Y Y
ANGPTL4 −0.422∗ −0.0336 0.01–1.57 Y Y
BAMBI −0.454∗∗ −0.2279 0.29–8.67 Y Y Y
BMPER −0.686∗∗ −0.0985 0.06–9.28 Y Y Y
COL1A1 −0.551∗∗ −7.2721 6.35–302 Y Y Y
COL1A2 −0.340∗ −10.771 14.6–632
FGFR1 −0.453∗∗ −0.2315 0.61–13.6 Y Y
FZD4 −0.477∗∗ −0.0789 0.07–12.2 Y Y
IGFBP3 −0.417∗ −5.1189 8.78–236 Y Y
JAG1 −0.465∗∗ −0.1876 0.25–27.0 Y
SFRP4 −0.511∗∗ −0.1091 0.004–35.4 Y Y Y
SORT1 −0.331∗ −0.1515 0.134–5.68 Y Y
#SPARC −0.753∗ −16.614 33.2–545 Y Y Y
TNFRSF11B −0.642∗∗ −0.7225 0.179–29.2 Y Y Y
Lower expression
closer to senescence
CEBPA 0.358∗ 0.0012 0.001–0.119 Y
SFRP1 0.369∗ 0.0034 0.002–0.634 Y
SOX2 0.390∗ 0.3751 0.005–22.9 Y
∗𝑝 < 0.05; ∗∗𝑝 < 0.01; Y (yes) = 𝑝 < 0.05; empty = no significance. #Strongest candidate for prediction model based on multiple correlations and steepest
gradient.
Table 3: Correlations of methylation levels of CpG islands in
relation to culture expansion.
CpG island PD PD-BS
GRM7 0.606∗∗ −0.567∗∗
CASR 0.527∗∗ −0.640∗∗
PRAMEF2 −0.946∗∗ 0.775∗∗
SELP −0.934∗∗ 0.737∗∗
CASP14 −0.916∗∗ 0.640∗∗
KRTAP13-3 −0.941∗∗ 0.661∗∗
∗∗𝑝 < 0.01.
Conversely, the relative expression levels of CEBPA and
FABP4 steadily declined indicating the loss of adipogenic
potential.
Throughout the cultivation period clonal osteoprogenitor
assays were performed and similar to our previous study
showed a gradual loss of CFU-O with increased passaging
[16]. However, both CFU-O numbers and calcium deposition
assays showed stronger correlations with PD-BS compared to
PD. This indicated that MSC osteogenic potential was more
related to remaining proliferation capacity (also determined
by donor age), than simply a culture’s time in vitro [7, 38].
Of the genes studied, SPARC was the best candidate
marker due to its functional correlations and additionally its
superior expression range (between early and late passage
cultures); however it could not provide 95% confidence for
predicting PD-BS alone. This leads to modelling with other
parameters: telomere and methylation markers. In spite of
literature supporting the loss of telomere length being a
feature of MSC replicative ageing [9, 10, 16] no correlation
was found in either culture expanded MSCs or osteod-
ifferentiated MSCs, although the differentiated MSCs did
have significantly shorter telomeres. Modelling calculations
in conjunction with SPARC were attempted but were not
predictive.
The methylation of CpG islands [12] collectively had
very strong associations with PD, which remained for PD-
BS albeit reduced; however for predictability PRAMEF2
provided the best indicator of remaining PD-BSwhen in con-
junction with SPARC (SPARC × [1/PRAMEF2]). PRAMEF2
currently has no known function and is one of several par-
alogous duplications of PRAMEF1 located on chromosome
1p36.21 [39]. It is arguable that the 2- and 72-year-old donors
may bias this study; however we further tested this model
without data from these donors’, and evenwith less data/lower
power the correlations and testing of the model remained
strong for SPARC × [1/PRAMEF2] (Supplementary Figure 6),
thus reinforcing the utility of this calculation.
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Figure 4: Combination of SPARC and other parameters with predictive potential for MSC culture longevity. (a) No relationship between T/S
ratio and PD-BS (left; solid: culture expanded, hollow: postosteogenic induction), but correlation between SPARC × [T/S ratio] and PD-BS
(solid line: linear regression; dotted line: 95% confidence). (b) Left: 95% confidence in calculated values of SPARC × [1/PRAMEF2] in relation
to PB-BS (shaded area ≤5 PD-BS); right: relationship between SPARC × [1/PRAMEF2] and CFU-O (c). Predictionmodel of calculation values
<5 being indicative of higher remaining PD-BS (left) and osteogenic potential (right). Whisker range 2.5%–97.5% confidence, line at median.
We acknowledge that in this study MSC culture expan-
sion was primarily performed with the addition of FGF2,
an additive used for clinical-grade MSC manufacture [13]
and known to maintain MSC stemness by inhibiting cellular
senescence and by promoting proliferation [40] but not to
affect MSC proliferative lifespan [19].The number of cultures
tested was comparable [41] or even higher than used in
previous predictive modelling studies [29] and uniquely a
broad age-range feature was incorporated into the study. In
vivo segmental bone defect animal model investigations will
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be ultimately needed to prove the translational value of the
proposed predictive formula prior to its application to human
clinical studies.
5. Conclusions
Since both proliferative and osteogenic capacity of MSCs
are important for bone tissue repair then it was essential to
understand how both factors relate to each other duringMSC
cultivation. This study confirmed that MSC cultivation leads
to a pronounced loss of the multipotency and adipogenic
lineage gene expression in BM MSCs. The fact that the
loss of osteoprogenitors correlated more with the remaining
culture’s lifespan than its time in culture suggests that donor
age influence cannot be ignored when culture effects on
osteogenesis are considered. This study developed a predic-
tive test of MSC culture longevity and associated osteogenic
capacity, irrespective of donor age. Similar to other predictive
assays proposed in the past [12, 29], this assay employs a
formula based on a combination of two parameters, in our
case gene expression level for SPARC and PRAMEF2. It
capitalises on the greatest expression range of SPARC across
time in culture, coupled with highly accurate CpG island
PRAMEF2. The fact that SPARC is unchanged between the
native CD271-positive BM MSCs and early passage MSCs
[17] suggests that this may be a viable test even before MSC
culturing.
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